AbbVie (ABBV)Officer sold ~$8.18M

~$8.18M

Approx. value · 33K sh @ $250.00

74K

Holds after · shares reported

Traded

Aug 14, 2026

Filed

Aug 18, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 27, 2026CongressDisclosed purchase of ABBV — reported range $15,001 - $50,000
2. Jun 18, 2026Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $3.6K obligated to date
3. Jun 26, 2026FDAFDA drug approval: Skyrizi
4. Jun 26, 2026Government · Federal Register noticeDetermination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
5. Jun 29, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
6. Jul 1, 2026Federal contract · $3K obligatedDepartment of Defense awarded AbbVie: $3.3K obligated to date
7. Jul 6, 2026Company filing · Form 8-K · ResultsReported its results
8. Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
9. Jul 7, 2026Government · Federal Register noticeCertain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation; Termination of Investigation
10. Jul 31, 2026Company filing · Form 8-K · ResultsReported its results
11. Aug 14, 2026 · this disclosureInsider · Their largest sale since 2023Officer sold ~$8.18M of ABBV shares in the open market

What came next

1. Sep 1, 2026Government · Federal Register noticeDetermination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
2. Sep 2, 2026Government · Federal Register noticeDetermination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
3. Sep 14, 2026CongressDisclosed sale of ABBV — reported range $15,001 - $50,000
4. Sep 25, 2026FDAFDA drug approval: Juvmo
5. Oct 5, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for AbbVie

For AbbVie, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports, 130 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

Other recent filings by Nicholas Donoghoe, EVP, CHIEF BUS/STRAT OFFICER

• SEC Form 4 at AbbVie (ABBV)Aug 7, 2025
• SEC Form 4 at AbbVie (ABBV)Aug 7, 2025

The full history of Nicholas Donoghoe, EVP, CHIEF BUS/STRAT OFFICER is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at AbbVie

• House Clerk periodic transaction reportSep 18, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 25, 2026
• SEC Form 13F-HRAug 17, 2026
• SEC Form 144Aug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its ABBV page.